Comparative Trials Urged By NEJM Departing Editor To Deter "Me-Too" Drugs

FDA should make new drug approvals based on comparisons to existing therapies in order to stem the tide of "me-too" medications being brought to market, New England Journal of Medicine Editor-In-Chief Marcia Angell, MD, said in the journal's June 22 issue.